[ad_1] STOCKHOLM , Dec. 5, 2024 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson’s disease patients. […]
Tag: BioArctic
First patient dosed in EXIST Phase 2a study in Parkinson’s disease
[ad_1] STOCKHOLM , Dec. 5, 2024 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson’s disease patients. […]
Leqembi® approved in Mexico
[ad_1] STOCKHOLM, Dec. 4, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) […]
Leqembi® approved in Mexico
[ad_1] STOCKHOLM, Dec. 5, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) […]
Leqembi® launched in South Korea
[ad_1] STOCKHOLM, Nov. 28, 2024 /PRNewswire/ – BioArctic AB’s (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced today that Leqembi® (generic name: lecanemab) has been launched in South Korea. Leqembi received approval in South Korea […]
